Thanks to the cBioPortal facilities for TCGA and the CellMinerCDB portal for CCLE and GDSC, it was possible: (i) to compare the levels of AGR2 and AGR3 expressions in various tumour types; (ii) to identify AGR2/3 expression variations in samples with SNV or CNV of these genes; (iii) to look for associations between AGR2/3 expression and that of other genes in selected tumour types and (iv) to identify associations between AGR2/3 and potentially oncogenic molecular features involving the whole exome, namely SNV and CNV. This evidence concerns the gene AGR3 and neoplasm.